Skip to main content
GrantTroveGrantTrove
FederalForecastedNational Institutes of Health

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Award ceiling
Not stated
Closes
Not stated
Last verified
2026-11-09

Per-recipient award not stated for city or township governments, county governments, for profit organizations other than small businesses, native american tribal governments (federally recognized), native american tribal organizations (other than federally recognized tribal governments), nonprofits having a 501(c)(3) status with the irs, other than institutions of higher education, nonprofits that do not have a 501(c)(3) status with the irs, other than institutions of higher education, others (see text field entitled "additional information on eligibility" for clarification), private institutions of higher education, public and state controlled institutions of higher education, small businesses, special district governments, state governments.

Official pageSign in to trackVerified2026-11-09
City or township governmentsCounty governmentsFor profit organizations other than small businessesNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Private institutions of higher educationPublic and State controlled institutions of higher educationSmall businessesSpecial district governmentsState governmentsHealth & Human Services

In one sentence

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) does not state a per-recipient award amount, open to city or township governments, county governments, for profit organizations other than small businesses, native american tribal…

Record fields
Program pool (total)
Not confirmed
Total across all awards in this programme. Not an amount any single applicant can receive.
Award ceiling (per project)
Not confirmed
Award floor
Not confirmed
Typical award
Not confirmed
Deadline
Not stated
Deadline type
Not stated
Opens
Mar 1, 2027
Status
Forecasted
Eligible entities
City or township governments · County governments · For profit organizations other than small businesses · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Public and State controlled institutions of higher education · Small businesses · Special district governments · State governments
Geography
Not stated
Matching funds
No
Disbursement
Not confirmed
Application effort
Not confirmed
Use of funds
Scientific research utilizing data from intermediate-size patient population expanded access protocols for ALS · Investigational drug's or biological product's effect on biomarkers related to the pathophysiology of ALS or target engagement · Collection of safety or outcome information, such as survival or other significant medical events · Patient experience data
Currency
USD

How much money is available?

Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.

Program pool (total)Across all awards this cycle
Not stated
Award ceiling (per project)The most one applicant can receive
Not stated

Who can apply?

level
federal
Derived from the source that published this record
entity
City or township governments, County governments, For profit organizations other than small businesses, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public and State controlled institutions of higher education
+3more, Small businesses, Special district governments, State governments
Source field: entity types
industry
Health & Human Services
Source field: industries
use
Collection of safety or outcome information, such as survival or other significant medical events, Investigational drug's or biological product's effect on biomarkers related to the pathophysiology of ALS or target engagement, Patient experience data, Scientific research utilizing data from intermediate-size patient population expanded access protocols for ALS
Source field: use of funds
size limit

Not confirmed

Source field: applicant size limit
clause text

Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to establish substantial evidence of effectiveness in support of a marketing…

We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.

When does it close?

Not statedDeadline type Not stated

Applications are not being solicited at this time

What can the money be used for?

4 categorysThe source’s own spending categories, and what is not parsed.
Scientific research utilizing data from intermediate-size patient population expanded access protocols for ALSInvestigational drug's or biological product's effect on biomarkers related to the pathophysiology of ALS or target engagementCollection of safety or outcome information, such as survival or other significant medical eventsPatient experience data

These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.

How hard is the application?

1 fieldEffort, match requirement and reimbursement, as the source stated them.
Application effort
Not confirmed
Disbursement
Not confirmed
Matching funds
No

What comparable notices state

296 recordsStated ceilings on open records in the same industry.

Among open records stored under Health & Human Services, 296 of 881 state an award ceiling. Those that do run:

  • 25th percentile$363,750
  • Median$600,000
  • 75th percentile$1,500,000

A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.

Common questions

3 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
Who is eligible to apply?
City or township governments, County governments, For profit organizations other than small businesses, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public and State controlled institutions of higher education, Small businesses, Special district governments, State governments.
What can the funding be used for?
Scientific research utilizing data from intermediate-size patient population expanded access protocols for ALS, Investigational drug's or biological product's effect on biomarkers related to the pathophysiology of ALS or target engagement, Collection of safety or outcome information, such as survival or other significant medical events, Patient experience data, as classified by the source.
Is matching funding required?
No. The source states that no matching funds are required.

AI summary of the source text

Optional. Every core field on this record is already above, free and complete.

AI summary of the source text

Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.

Included with Studio

Sign in

What else is open

Also open from National Institutes of Health
Provenance
Source pagegrants.gov
Retrieved2026-11-09
MethodAutomated check
First seen2026-09-24

The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.

Cite this record

Copy this page reference for your research notes. Follow the source links on this page to verify the underlying figures and reporting years.

GrantTrove. Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required). https://granttrove.com/grants/363926. Record last checked: 2026-11-09. Confirm the current application window and all requirements against the linked source notice.